Latest European Society of Cardiology Stories

New strategies injecting cardiovascular disease (CVD) patients with vaccines and monoclonal antibodies to combat atherosclerosis could soon change the treatment landscape of heart disease. Both approaches, Professor Jan Nilsson told delegates at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, can be considered truly ground breaking since for the first time they target the underlying cause of CVD. The FCVB meeting, organized by the Council on Basic Cardiovascular Science (CBCS) of...

LONDON, March 26, 2012 /PRNewswire/ -- Results presented from new VOYAGER sub-analysis This release is INTENDED EXCLUSIVELY FOR EUROPEAN media AstraZeneca today announced the results of a sub-analysis from the VOYAGER individual patient data meta-analysis, which suggests that achieving an LDL-C goal of <70 mg/dL or >50% reduction in LDL-C levels in patients at high risk requires aggressive statin therapy. These goals...

Groundbreaking white paper by the European Society of Cardiology In a groundbreaking White Paper published today in the European Heart Journal, the European Society of Cardiology (ESC) has set out its perspective on the relationship between the healthcare industry and professional medical associations with regard to the funding and delivery of continuing medical education (CME). Essential in helping to reduce the burden of cardiovascular disease across Europe – the ESC's over-arching...

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure¹. In the "hypothesis generating" study, ursodeoxycholic acid (UDCA) delivered significant improvements in peak post ischemic blood flow in the arm, a trend for improvement in peak post ischemic blood flow in the leg, but failed to show benefits in exercise...

European Society of Cardiology extends its scientific activities beyond Europe and into the emerging regions of the world While the rapid improvement in socio-economic conditions is thought responsible for the high rates of cardiovascular disease in the Gulf states, deep-rooted cultural factors also play a part. "We're sitting on a time bomb," says Professor Hani Najm, Vice-President of the Saudi Heart Association, whose annual conference begins Friday 27 January. "We will see a lot of...

The ESC welcomes the spotlight that a US study has placed on the importance of measuring rates of rehospitalization following PCI procedures The European Society of Cardiology (ESC) welcomes the spotlight that a US study has placed on the importance of measuring rates of rehospitalization following percutaneous coronary intervention (PCI) procedures. The research, published today in JACC Cardiovascular Interventions¹, represents one of the first studies to explore PCI readmissions and...

The European Chronic Disease Alliance welcomes the UN High Level Meeting on Non-Communicable Diseases to address the world's biggest killers The European Chronic Disease Alliance (ECDA) welcomes the UN High Level Meeting on Non Communicable Diseases (NCDs) to address the world biggest killers. "It is a memorable day in the history of public health. Discussing non communicable diseases at the UN table gives a strong sense of the burden it represents to human kind and the recognition that...

TSX Exchange Symbol: RVX CALGARY, Sept. 1, 2011 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX: RVX) announced today that two abstracts on the analysis of the ASSERT trial were presented at the European Society of Cardiology (ESC) Congress 2011 in Paris, France. The abstracts were co-authored by Resverlogix Senior Scientists and Clinical Steering Committee members: S.J. Nicholls, A. Gordon, J. Johansson, C.M. Ballantyne, J.J.P. Kastelein, N.C.W. Wong, M. Borgman, K....

Outcomes in GRAVITAS trial Compared to patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence of cardiovascular death, heart attack and stent thrombosis, as indicated by a clinical trial presented today at the ESC Congress 2011. These findings were part of a secondary analysis of the Gauging Responsiveness with A VerifyNow P2Y12 Assay- Impact on Thrombosis and Safety (GRAVITAS)...

A report from the nationwide complete Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Results from the SCAAR study, presented at the ESC Congress 2011 today, showed that Percutaneous Coronary Intervention (PCI) with "new generation" Drug Eluting Stents, was associated with a 38% lower risk of clinically meaningful restenosis and a 50% lower risk of stent thrombosis compared to old generation DES. Although many trials and studies support the overall early and mid-term...